@article{9aa782d5ef854db9ad368c66213c7a85,
title = "Quantitative assessment of field strength, total intracranial volume, sex, and age effects on the goodness of harmonization for volumetric analysis on the ADNI database",
abstract = "When analyzing large multicenter databases, the effects of multiple confounding covariates increase the variability in the data and may reduce the ability to detect changes due to the actual effect of interest, for example, changes due to disease. Efficient ways to evaluate the effect of covariates toward the data harmonization are therefore important. In this article, we showcase techniques to assess the “goodness of harmonization” of covariates. We analyze 7,656 MR images in the multisite, multiscanner Alzheimer's Disease Neuroimaging Initiative (ADNI) database. We present a comparison of three methods for estimating total intracranial volume to assess their robustness and correct the brain structure volumes using the residual method and the proportional (normalization by division) method. We then evaluated the distribution of brain structure volumes over the entire ADNI database before and after accounting for multiple covariates such as total intracranial volume, scanner field strength, sex, and age using two techniques: (a) Zscapes, a panoramic visualization technique to analyze the entire database and (b) empirical cumulative distributions functions. The results from this study highlight the importance of assessing the goodness of data harmonization as a necessary preprocessing step when pooling large data set with multiple covariates, prior to further statistical data analysis.",
keywords = "LDDMM, data harmonization, field strength, magnetic resonance imaging, multi-atlas fusion, total intracranial volume",
author = "{Alzheimer's Disease Neuroimaging Initiative} and Da Ma and Karteek Popuri and Mahadev Bhalla and Oshin Sangha and Donghuan Lu and Jiguo Cao and Claudia Jacova and Lei Wang and Beg, {Mirza Faisal}",
note = "Funding Information: information: Alzheimer's Disease Neuroimaging Initiative, Grant/Award Number: Department of Defense award number W81XWH-12-2-001, National Institutes of Health Grant U01 AG024904; Canadian Institutes of Health Research (CIHR) operating grant #179009 and #74580; Canada Brain Research Fund (CBRF), Brain Canada Foundation; Michael Smith Foundation for Health Research (MSFHR); Natural Sciences and Engineering Research Council of Canada (NSERC); Pacific Alzheimer Research Foundation (PARF center grant C06-01); Alzheimer Society Research Program (ASRP), Alzheimer Society of Canada; DOD ADNI, Grant/Award Number: W81XWH-12-2-0012; National Institutes of Health, Grant/Award Number: U01 AG024904; National Institute on Aging, Grant/Award Number: R01 AG055121-01A1Funding for this research is gratefully acknowledged from Canadian Institutes of Health Research (CIHR, operating grant #179009 and #74580); Canada Brain Research Fund (CBRF), Brain Canada Foundation; Pacific Alzheimer Research Foundation (PARF, center grant C06-01); Michael Smith Foundation for Health Research (MSFHR); Natural Sciences and Engineering Research Council of Canada (NSERC); Alzheimer Society Research Program (ASRP), Alzheimer Society of Canada; National Institute of Aging (R01 AG055121-01A1). The authors would like to thank Compute Canada for the computational infrastructure provided for the data processing in this study. Data collection and sharing for this project was funded by the Alzheimers Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging, and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimers Association; Alzheimers Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Funding Information: Alzheimer's Disease Neuroimaging Initiative, Grant/Award Numbers: Department of Defense award number W81XWH-12-2-001, National Institutes of Health Grant U01 AG024904; Canadian Institutes of Health Research (CIHR) operating grant #179009 and #74580; Canada Brain Research Fund (CBRF), Brain Canada Foundation; Michael Smith Foundation for Health Research (MSFHR); Natural Sciences and Engineering Research Council of Canada (NSERC); Pacific Alzheimer Research Foundation (PARF center grant C06-01); Alzheimer Society Research Program (ASRP), Alzheimer Society of Canada; DOD ADNI, Grant/Award Number: W81XWH-12-2-0012; National Institutes of Health, Grant/Award Number: U01 AG024904; National Institute on Aging, Grant/Award Number: R01 AG055121-01A1 Funding Information: Funding for this research is gratefully acknowledged from Canadian Institutes of Health Research (CIHR, operating grant #179009 and #74580); Canada Brain Research Fund (CBRF), Brain Canada Foundation; Pacific Alzheimer Research Foundation (PARF, center grant C06-01); Michael Smith Foundation for Health Research (MSFHR); Natural Sciences and Engineering Research Council of Canada (NSERC); Alzheimer Society Research Program (ASRP), Alzheimer Society of Canada; National Institute of Aging (R01 AG055121-01A1). The authors would like to thank Compute Canada for the computational infrastructure provided for the data processing in this study. Data collection and sharing for this project was funded by the Alzheimers Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging, and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimers Association; Alzheimers Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Publisher Copyright: {\textcopyright} 2018 Wiley Periodicals, Inc.",
year = "2019",
month = apr,
day = "1",
doi = "10.1002/hbm.24463",
language = "English (US)",
volume = "40",
pages = "1507--1527",
journal = "Human Brain Mapping",
issn = "1065-9471",
publisher = "Wiley-Liss Inc.",
number = "5",
}